Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
All content for MyeConversations by Myeloma Australia is the property of Myeloma Australia and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
S02 E08: Clinical Trials and access when you live regionally
MyeConversations by Myeloma Australia
50 minutes
3 years ago
S02 E08: Clinical Trials and access when you live regionally
In this episode we meet Dr Hasib Sidiqi from Fiona Stanley Hospital in Perth, Western Australia. We will be talking about clinical trials and why they’re so important as an option of therapy for people living with myeloma. We will delve into the structure and phases of clinical trials, eligibility for trials and some of the pro’s and cons of being involved in a clinical trial. We will also find out about some of the trials happening now in Australia for the myeloma community and how to know w...
MyeConversations by Myeloma Australia
Part 2: Narelle Smith and Professor Gordon Cook continue their discussion on the use of Autologous Stem Cell Transplant (AuSCT) in treating myeloma. This episode covers the key differences between AuSCT, allogeneic stem cell transplant, and CAR-T cell therapy, and concludes with a look at the role of maintenance therapy following an AuSCT.
